Pharmacogenetic pathway analysis for determination of sunitinib-induced toxicity. - Wikidata - awgldk - TriplyDB

Pharmacogenetic pathway analysis for determination of sunitinib-induced toxicity.

Pharmacogenetic pathway analysis for determination of sunitinib-induced toxicity.

http://www.wikidata.org/entity/Q27851481

about

Systems pharmacology: network analysis to identify multiscale mechanisms of drug action Mammalian target of rapamycin inhibitor-associated stomatitis Pharmacogenetic biomarkers for the prediction of response to antiangiogenic treatment Individualising treatment choices in a crowded treatment algorithm CIViC database Influence of Tyrosine Kinase Inhibitors on Hypertension and Nephrotoxicity in Metastatic Renal Cell Cancer Patients Early sorafenib-induced toxicity is associated with drug exposure and UGTIA9 genetic polymorphism in patients with solid tumors: a preliminary study Sunitinib as a second-line therapy for advanced GISTs after failure of imatinib: relationship between efficacy and tumor genotype in Korean patients.Matrix metalloproteinase-2 polymorphisms and clinical outcome of Chinese patients with nonsmall cell lung cancer treated with first-line, platinum-based chemotherapy.Understanding, recognizing, and managing toxicities of targeted anticancer therapies.Pharmacogenetic determinants associated with sunitinib-induced toxicity and ethnic difference in Korean metastatic renal cell carcinoma patients.Sunitinib in metastatic renal cell carcinoma: an ethnic Asian subpopulation analysis for safety and efficacy.Role of the lean body mass and of pharmacogenetic variants on the pharmacokinetics and pharmacodynamics of sunitinib in cancer patients.Polymorphisms in SLCO1B3 and NR1I2 as genetic determinants of hematotoxicity of carboplatin and paclitaxel combination.Pharmacokinetically guided sunitinib dosing: a feasibility study in patients with advanced solid tumours.Identifying novel genes and biological processes relevant to the development of cancer therapy-induced mucositis: An informative gene network analysis.Association of VEGF and VEGFR2 single nucleotide polymorphisms with hypertension and clinical outcome in metastatic clear cell renal cell carcinoma patients treated with sunitinib.Anti-angiogenic tyrosine kinase inhibitors: what is their mechanism of action?A phase I study of sunitinib plus capecitabine in patients with advanced solid tumors A phase I dose-escalation study to evaluate safety and tolerability of sorafenib combined with sirolimus in patients with advanced solid cancer.Polymorphisms in endothelial nitric oxide synthase (eNOS) and vascular endothelial growth factor (VEGF) predict sunitinib-induced hypertension.Tyrosine kinase inhibitors: Multi-targeted or single-targeted?Current progress in pharmacogenetics.Germline variation in cancer-susceptibility genes in a healthy, ancestrally diverse cohort: implications for individual genome sequencing.A case of metastatic renal cell carcinoma and bile duct carcinoma treated with a combination of sunitinib and gemcitabine.Oral adverse events associated with tyrosine kinase and mammalian target of rapamycin inhibitors in renal cell carcinoma: a structured literature review.Interaction of innovative small molecule drugs used for cancer therapy with drug transporters.Association of ABCB1 and FLT3 Polymorphisms with Toxicities and Survival in Asian Patients Receiving Sunitinib for Renal Cell Carcinoma.Randomised phase II trial of docetaxel and sunitinib in patients with metastatic gastric cancer who were previously treated with fluoropyrimidine and platinum.Efflux transporter variants as predictors of drug toxicity in lung cancer patients: systematic review and meta-analysis.Variability of sorafenib toxicity and exposure over time: a pharmacokinetic/pharmacodynamic analysis Association of single nucleotide polymorphisms in IL8 and IL13 with sunitinib-induced toxicity in patients with metastatic renal cell carcinoma.Biomarkers for tyrosine kinase inhibitors in renal cell cancer.The influence of genetic variants of sorafenib on clinical outcomes and toxic effects in patients with advanced renal cell carcinoma.Everolimus pharmacokinetics and its exposure-toxicity relationship in patients with thyroid cancer.Methylomes of renal cell lines and tumors or metastases differ significantly with impact on pharmacogenes Buccodental side effects of sunitinib in patients with metastatic renal cell carcinoma Meta-analysis on the association of VEGFR1 genetic variants with sunitinib outcome in metastatic renal cell carcinoma patients.Oral mucositis: the new paradigms.Drug transport by breast cancer resistance protein.

P2860

Q26824166-F975E0DA-307C-41E5-99A0-32F56850DECB Q26825301-5A4A8BC3-D7F9-44A6-A992-B6349593228F Q26996793-3303B158-BFD9-4850-BEDB-D6452CCB96AF Q27023669-E7403E04-1AAF-4B57-8AE2-66FAA3555088 Q27612411-5EBE4B6A-D6C2-4AD1-9F19-93945CAB1DBA Q28080163-8A4480C7-5137-43A0-8D2D-6A1BB4541392 Q28482219-ACF00E45-3595-4DD7-AE4C-E9701FBAC7F0 Q33392955-CADD972D-6CBB-49B8-950B-79D81B59E1C0 Q33398142-0622CAE7-6314-488B-B151-482149D69F85 Q33408049-8DC29CA9-A419-4AB7-9E1F-A4A23AEA8A63 Q33410206-A1B269F1-76FF-44E1-A08E-8D75429CEF96 Q33413566-7A68B5ED-7315-4062-B62F-F09A2E31D0A3 Q33418378-2A606079-BB77-432A-A919-91B455EB4BF8 Q33425137-4E48B149-9C38-47CA-9B2F-889ACFD8AE5D Q33613666-B2DC35D4-0B9B-4E5A-8EF0-C0F1FD533558 Q33874148-84DF9F90-A2C9-4DDF-81B7-3DF3D47297FC Q34013801-2D932BDC-585D-40B5-B015-0057DAA878CA Q34088265-9535CFBE-0922-45C5-943E-38B689105261 Q34334959-161264AE-32B2-4AE2-91EA-0E1D1F79249C Q34363435-472B663F-7428-4AEF-99A9-CEC0D7103495 Q34403301-08E79DF1-29E8-403C-AB08-B74C0AFA4665 Q34983846-23AC4077-A66B-4BD4-B978-2EDE721971AB Q34996898-FB0BEC73-8C71-41D6-9B45-65BF884A51DC Q35146870-EA373F0D-3A0A-4C19-A7DF-26C9DC368694 Q35639659-FEF4F1E7-B718-48A0-91C5-A3D0118463BC Q35705188-D8762C63-49DD-4F29-B0ED-D1ADC31B1F4C Q35708124-D97AACBE-9200-4987-B4B6-B5CFB1C1A1D6 Q35921573-79790CB8-C788-4C9E-9622-94A99E19F1B9 Q35927364-AF9C1DF7-06B2-4D21-B390-96C6FA198D93 Q36043023-4396A1B3-B3AD-416E-954E-4EB94416DB08 Q36251480-6CC402BF-064A-460D-8405-5176FFDF93C5 Q36275134-B78CF9A8-5CA1-41DA-B662-F4CACDDD878B Q36450612-9DF6D7FE-6ADD-4BE8-B8D8-FBD4E7C08324 Q36528151-94DEBFE4-E18D-472D-B304-60155F3CF23F Q37038195-2A6EE0C8-A041-49C1-BA33-EAF1081020FA Q37110909-F89B99F3-0D8E-493A-AD23-3DB577F0E9AA Q37214287-B3DB0FC7-E487-4BBB-A90A-B8C67E64AF68 Q37702070-D32EB1D6-717C-47B6-9EBC-5AB189A98A90 Q37756485-315CE8F9-A3B6-43D3-8DDA-EA70235EDE90 Q37793056-93A3A360-5804-4102-9700-F9C0C30761B5

P2860

Pharmacogenetic pathway analysis for determination of sunitinib-induced toxicity.

http://www.wikidata.org/entity/Q27851481

description

2009 nî lūn-bûn

@nan

2009 թուականի Սեպտեմբերին հրատարակուած գիտական յօդուած

@hyw

2009 թվականի սեպտեմբերին հրատարակված գիտական հոդված

@hy

2009年の論文

@ja

2009年論文

@yue

2009年論文

@zh-hant

2009年論文

@zh-hk

2009年論文

@zh-mo

2009年論文

@zh-tw

2009年论文

@wuu

name

Pharmacogenetic pathway analysis for determination of sunitinib-induced toxicity.

@ast

Pharmacogenetic pathway analysis for determination of sunitinib-induced toxicity.

@en

Pharmacogenetic pathway analysis for determination of sunitinib-induced toxicity.

@nl

type

label

Pharmacogenetic pathway analysis for determination of sunitinib-induced toxicity.

@ast

Pharmacogenetic pathway analysis for determination of sunitinib-induced toxicity.

@en

Pharmacogenetic pathway analysis for determination of sunitinib-induced toxicity.

@nl

prefLabel

Pharmacogenetic pathway analysis for determination of sunitinib-induced toxicity.

@ast

Pharmacogenetic pathway analysis for determination of sunitinib-induced toxicity.

@en

Pharmacogenetic pathway analysis for determination of sunitinib-induced toxicity.

@nl

P1433

Q27851481-644CBD59-2904-4E00-A4B4-53E14DBAC6C4

P1476

Q27851481-89B40712-D55B-4198-B293-C072C683619B

P2093

Q27851481-05B556CE-F9BD-46A2-A87C-53132C850A5A

Q27851481-23471921-888A-49A6-B9F1-0ACB5124E4DE

Q27851481-2523CA59-7AFA-40FF-85F1-413A764A9F83

Q27851481-409751A1-4BCE-46F6-A4E8-13584172515F

Q27851481-5F220B79-130F-45D6-8C4D-3DD3932A6A82

Q27851481-6FAEC5E8-D848-4546-B93F-5EFD0474B38A

Q27851481-8CB9E1B2-779A-4E20-8BD0-9C0675088901

Q27851481-904B56D9-6987-4A97-8B0D-FF0C7A0F7D83

Q27851481-B1186424-FBE0-4DC4-82B8-26FF0D7703CE

Q27851481-CF6A21A2-372C-4EAC-84E5-C3B351AA78F2

P304

Q27851481-C5BBE169-D5CF-45A3-A6FB-44A085598D57

P31

Q27851481-A0D5C3B7-D53A-488C-9CBB-288B24D40959

P3181

Q27851481-273B056C-853B-4532-A3A0-632B4AA42064

P356

Q27851481-8E8B7A0B-7809-4E7C-AF1B-9868C4B59102

P407

Q27851481-E6C82AD1-63E3-4778-8025-DC5DFC6C4A9D

P433

Q27851481-B3FFCFD8-36ED-4537-9AFB-CE0DD64A0316

P478

Q27851481-D7EB8C25-0FB3-4C79-B719-B6ABA18E7829

P50

Q27851481-C04A0366-A1A0-47C8-BED8-868518BB4BF5

P577

Q27851481-6C617F2D-8700-4E1D-82AE-9E4C2EF2CE66

P698

Q27851481-F5CC47A4-B59F-424C-AFC6-A8D67B12DF3B

P3181

P356

JCO.2008.21.7679

P1433

Journal of Clinical Oncology

P1476

Pharmacogenetic pathway analysis for determination of sunitinib-induced toxicity.

@en

P2093

An K L Reyners

http://www.w3.org/2001/XMLSchema#string

Astrid A van der Veldt

http://www.w3.org/2001/XMLSchema#string

Epie Boven

http://www.w3.org/2001/XMLSchema#string

Hans Gelderblom

http://www.w3.org/2001/XMLSchema#string

John B Haanen

http://www.w3.org/2001/XMLSchema#string

Judith A M Wessels

http://www.w3.org/2001/XMLSchema#string

Karel Eechoute

http://www.w3.org/2001/XMLSchema#string

Nielka P van Erp

http://www.w3.org/2001/XMLSchema#string

Renée F Baak-Pablo

http://www.w3.org/2001/XMLSchema#string

Ron H J Mathijssen

http://www.w3.org/2001/XMLSchema#string

P304

4406-12

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P3181

1717794

http://www.w3.org/2001/XMLSchema#string

P356

10.1200/JCO.2008.21.7679

http://www.w3.org/2001/XMLSchema#string

P407

P433

26

http://www.w3.org/2001/XMLSchema#string

P478

27

http://www.w3.org/2001/XMLSchema#string

P50

Henk-Jan Guchelaar

P577

2009-09-10T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

19667267

http://www.w3.org/2001/XMLSchema#string